Published in Drug Week, August 1st, 2003
According to a study from the United States, "AMD473 (ZD0473; cis-amminedichloro[2-methylpyridine]-platinum [II]) is a new generation anticancer agent that, in preclinical studies, shows evidence of an extended spectrum of antitumor activity and overcomes platinum resistance mechanisms.
"Here we evaluate the activity of AMD473 (ZD0473) in a panel of 120 human tumor specimens using a soft agar cloning assay (human tumor colony-forming assay). When tumor cells were treated with 1.0, 4.0 or 16.0 micro g/ml AMD473 (ZD0473) for 2 h, in vitro responses were observed in 18%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week